Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble
antibody-drug conjugates
Biotech
NextCure advances ADC pivot with $745M deal for phase 1 drug
NextCure has ramped up its ADC pivot, penning a $745 million deal for the ex-China rights to Simcere Zaiming’s phase 1-stage tumor asset.
James Waldron
Jun 16, 2025 9:52am
To Gilead's new CMO, pipeline diversification is key
Jun 9, 2025 10:00am
TegMine bags tech from OBI to help fuel ADC ambitions
Jun 6, 2025 10:00am
Merck takes middle dose of ROR ADC forward into phase 3
May 30, 2025 9:51am
Endometrial cancer data on Genmab's Elahere rival beat forecast
May 23, 2025 9:22am
ADC Therapeutics calls time on sole clinical-stage candidate
May 14, 2025 9:55am
